## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.88 indicates fundamental undervaluation.

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($312.71)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Elevance Health, Inc. (ELV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation**
- Source: KLAS 8 News Now | 20251207T160812 | Neutral | Relevance: 97%
-  Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Elevance Health, Inc. (NYSE: ELV) on behalf of investors who purchased securities before April 18, 2024, and still hold them. The investigation seeks to determine if Elevance and its officers engaged in corporate wrongdoing. Shareholders are encouraged to contact the firm for more information.

**2. Elevance Health expands virtual assistant access for care services**
- Source: Yahoo | 20251208T101028 | Bullish | Relevance: 97%
-  Elevance Health has expanded the availability of its virtual assistant to nearly 22 million members with commercial health plans, aiming to simplify obtaining information, clarifying benefits, and locating care services. The virtual assistant utilizes conversational technology and is accessible via the company's affiliated health plan websites and the Sydney Health app, with early data indicating high user satisfaction. Plans are in place to extend access to Medicare members in 2026, contingent on state approvals.

**3. Can UNH's AI-Powered Virtual Assistance Enhance Member Experience?**
- Source: TradingView | 20251208T160808 | Somewhat-Bullish | Relevance: 80%
-  UnitedHealth Group (UNH) is integrating AI-powered virtual assistance to improve member experience by streamlining benefit navigation and healthcare choices. This initiative aims to automate routine tasks like checking claim status and finding in-network doctors, reducing call-center load and enhancing digital engagement. Competitors like Elevance Health and Humana are also expanding their AI healthcare solutions to offer more intuitive and personalized member interactions.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Long-term trend broken: trading 7.8% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.88 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $74.4B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.88 |
| Forward P/E | 12.1 |
| Current P/E | 11.0 |
| YoY Growth | -9.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.7% over 5 days). Below STRENGTH zone by 4.8pp (needs >4.0% for momentum thesis). Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (0.81), confirming momentum. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.83% (CS: 51) | Neutral |
| RSI_14 | 51.3 | Neutral |
| MACD Histogram | 0.81 | Bullish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 0.989x | Below |
| vs SMA200 | 0.922x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $330.61
- **Stop Loss:** $312.71 (5.4% risk)
- **Target:** $366.41 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 27
- **Position Value:** $8,926.47
- **Portfolio %:** 8.93%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*